ESR1 and breast carcinoma: (17) conducted a phase 3, open-label, multicenter trial involving premenopausal women with estrogen receptor-positive breast cancer who were administered a 3-month 10.8-mg dose (n = 109) and a monthly 3.6-mg dose of goserelin (n = 113).